title: Practice parameter: treatment of the child with a first unprovoked seizure: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
abstract: The Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society develop practice parameters as strategies for patient management based on analysis of evidence regarding risks and benefits. This parameter reviews published literature relevant to the decision to begin treatment after a child or adolescent experiences a first unprovoked seizure and presents evidence-based practice recommendations. Reasons why treatment may be considered are discussed. Evidence is reviewed concerning risk of recurrence as well as effect of treatment on prevention of recurrence and development of chronic epilepsy. Studies of side effects of anticonvulsants commonly used to treat seizures in children are also reviewed. Relevant articles are classified according to the Quality Standards Subcommittee classification scheme. Treatment after a first unprovoked seizure appears to decrease the risk of a second seizure, but there are few data from studies involving only children. There appears to be no benefit of treatment with regard to the prognosis for long-term seizure remission. Antiepileptic drugs (AED) carry risks of side effects that are particularly important in children. The decision as to whether or not to treat children and adolescents who have experienced a first unprovoked seizure must be based on a risk-benefit assessment that weighs the risk of having another seizure against the risk of chronic AED therapy. The decision should be individualized and take into account both medical issues and patient and family preference.
authors.affiliation: National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
authors.forename: D
authors.initials: D
authors.lastname: Hirtz
authors.forename: A
authors.initials: A
authors.lastname: Berg
authors.forename: D
authors.initials: D
authors.lastname: Bettis
authors.forename: C
authors.initials: C
authors.lastname: Camfield
authors.forename: P
authors.initials: P
authors.lastname: Camfield
authors.forename: P
authors.initials: P
authors.lastname: Crumrine
authors.forename: W D
authors.initials: WD
authors.lastname: Gaillard
authors.forename: S
authors.initials: S
authors.lastname: Schneider
authors.forename: S
authors.initials: S
authors.lastname: Shinnar
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use*; D001519:Behavior / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003071:Cognition / Q000187:drug effects; D015331:Cohort Studies; D003875:Drug Eruptions; D005500:Follow-Up Studies; D006801:Humans; D011379:Prognosis; D012074:Remission Induction; D018570:Risk Assessment; D055502:Secondary Prevention; D012640:Seizures / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D012894:Sleep Stages / Q000187:drug effects; D016896:Treatment Outcome; D014481:United States
chemical_list: D000927:Anticonvulsants